The Death of Investing in Heart Surgery: An Exaggerated Demise
This article was originally published in Start Up
Over the past several years, new tools have helped interventional cardiologists capture patients who historically would have been candidates for surgery. Drug-eluting stents are apt to only increase this trend. These technology innovations have sparked the latest round of proclamations that there is no future in cardiac surgery since the sector's largest component--bypass--is waning, and that the only worthwhile coronary device investment opportunities lie in products with interventional applications. Yet cardiac surgery remains a major device opportunity. A significant increase in M&A activity and recent later-round financings by companies like Percardia and Converge indicate that investing in cardiac surgery start-ups remains alive and well, albeit with new challenges. Indeed, some investors believe that heart surgeons, traditionally conservative adopters of new technology, are now more receptive than ever to new devices and procedures because of the threat to their livelihoods posed by interventionalists' increased encroaching on surgeons' core patients.
You may also be interested in...
Cardica: Rebuilding the Cardiac Surgery Market
The predicted expansion of beating-heart and minimally-invasive cardiac surgery never materialized, a result, some say, of the lack of safe and effective automated anastomotic tools. Cardica believes it has the answer that can at long last grow this market.
Magenta Medical Corp.
Magenta Medical is developing a device that provides hemostasis during minimally-invasive off pump coronary artery bypass graft surgery, without the use of an aortic clamp. Its founder is Dartmouth interventional cardiologist-entrepreneur Aaron Kaplan, whose previous start-ups include LocalMed and Perclose.
In Brief February 2007
A short summary of recent clinical and market developments in the medical device industry.